XML 48 R37.htm IDEA: XBRL DOCUMENT v3.21.2
SHAREHOLDERS' EQUITY (Narrative) (Details)
1 Months Ended 9 Months Ended 12 Months Ended
Feb. 22, 2021
USD ($)
$ / shares
shares
Jul. 31, 2020
USD ($)
$ / shares
shares
Aug. 27, 2019
USD ($)
$ / shares
shares
Jan. 31, 2016
$ / shares
shares
Jun. 30, 2021
USD ($)
$ / shares
shares
Jun. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
shares
SHAREHOLDERS' EQUITY              
Aggregate gross proceeds | $         $ 149,999,985 $ 0  
Share issuance transaction costs | $         $ 9,229,451 $ 314,603  
Options granted         1,889,646 4,218,000 4,218,000
Weighted average fair value of options granted | $ / shares         $ 9.87 $ 3.31  
Employee Share Purchase Plan [Member]              
SHAREHOLDERS' EQUITY              
Number of new stock issued during the period upon the exercise of Purchase Rights         10,702 16,506  
Offering term         9 months    
Maximum eligibility to common shares amount | $         $ 25,000    
Stock Options [Member]              
SHAREHOLDERS' EQUITY              
Option expiration period         10 years    
RSU's [Member]              
SHAREHOLDERS' EQUITY              
RSUs outstanding         0    
Minimum [Member] | Employee Share Purchase Plan [Member]              
SHAREHOLDERS' EQUITY              
Price percentage of common share granted         85.00%    
Maximum [Member] | Employee Share Purchase Plan [Member]              
SHAREHOLDERS' EQUITY              
Common shares reserved for issuance         252,418 284,887  
Employee contribution percentage         15.00%    
Maximum [Member] | Stock Options and RSU Plan [Member]              
SHAREHOLDERS' EQUITY              
Common shares reserved for issuance         7,342,788    
February 2021 Financing [Member]              
SHAREHOLDERS' EQUITY              
Aggregate gross proceeds | $ $ 149,999,985            
Shares issued 5,555,555            
Offering price per share | $ / shares $ 27.00            
Underwriter option to purchase additional securities 724,637            
Term of underwriters option 30 days            
Cash commissions paid | $ $ 8,999,999            
Share issuance transaction costs | $ $ 229,451            
July 2020 Financing [Member]              
SHAREHOLDERS' EQUITY              
Aggregate gross proceeds | $   $ 48,990,000          
Shares issued   7,100,000          
Offering price per share | $ / shares   $ 6.00          
Underwriter option to purchase additional securities   1,065,000          
Term of underwriters option   30 days          
Cash commissions paid | $   $ 2,939,400          
Share issuance transaction costs | $   $ 212,256          
August 2019 Financing [Member]              
SHAREHOLDERS' EQUITY              
Aggregate gross proceeds | $     $ 36,000,000        
Shares issued     6,080,596        
Offering price per share | $ / shares     $ 2.00        
Number of pre funded warrants issued     11,919,404        
Conversion of each prefunded warrant into common share     1        
Term of warrant     5 years        
Cash commissions paid | $     $ 1,978,770        
Share issuance transaction costs | $     $ 698,162        
Private Placement [Member]              
SHAREHOLDERS' EQUITY              
Shares issued       227,273      
Offering price per share | $ / shares       $ 66.00      
Number of Units issued       227,273      
Units issued in private placement, conversion ratio       1      
Private Placement [Member] | 2 Year Warrants [Member]              
SHAREHOLDERS' EQUITY              
Term of warrant       2 years      
Units issued in private placement, conversion ratio       0.5      
Private Placement [Member] | 7 Year Warrants [Member]              
SHAREHOLDERS' EQUITY              
Term of warrant       7 years      
Units issued in private placement, conversion ratio       1      
Private Placement [Member] | Clarus Lifesciences III, L.P [Member]              
SHAREHOLDERS' EQUITY              
Number of shares acquired by shareholders       106,061      
Minimum number of shares required to be held for nomination rights       53,030